Norwegian Man Achieves Long-Term HIV Remission After Stem Cell Transplant

A man in Norway has reportedly achieved a functional cure for HIV following a stem cell transplant from his brother, adding to a limited but growing list of similar cases worldwide. This breakthrough offers new insights into the potential pathways for HIV remission, although it remains impractical as a widespread treatment option.

HIV, or human immunodeficiency virus, is a viral infection that attacks the immune system, potentially leading to AIDS (acquired immunodeficiency syndrome) if not treated. While advancements in prevention and treatment—such as pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART)—have significantly improved the lives of those living with HIV, a definitive cure has remained elusive. However, some rare cases have shown that stem cell transplants can lead to long-term remission.

The individual, known as the “Oslo patient,” is a 63-year-old man who has been in remission for five years after undergoing a hematopoietic stem cell transplant to treat myelodysplastic syndrome, a type of blood cancer. His case has been documented in the journal Nature Microbiology, marking the first instance of HIV remission following a transplant from a sibling. Extensive testing of blood, gut, and bone marrow samples showed no detectable viral reservoirs, confirming his remission status.

Most documented cases of HIV remission involving stem cell transplants have been linked to donors with a rare genetic mutation called CCR5Δ32. This mutation provides resistance to the most common forms of HIV by preventing the virus from entering immune cells. In this case, the Oslo patient received stem cells from his brother, who possesses this mutation.

Experts in the field, including Dr. Steven Deeks from UCSF, emphasize that while there have been ten successful transplants leading to HIV remission, each case is unique. The collective findings show that various mechanisms may contribute to a potential cure. Dr. Augusto Dulanto, from Vanderbilt University, views this case as a hopeful development in HIV research.

The process of hematopoietic stem cell transplantation typically involves chemotherapy or radiation to eliminate the patient’s existing bone marrow and immune system, followed by the infusion of healthy donor stem cells. This can drastically reduce the number of cells harboring HIV. In some cases, even patients without the CCR5Δ32 mutation have achieved remission, potentially due to immune responses triggered by the transplant itself.

Despite its promise, researchers caution that HSCT is not a scalable solution for HIV treatment. The procedure carries significant risks, including a mortality rate of 10-20% within the first year and the possibility of cancer relapse. While ART remains the most effective and accessible treatment for HIV today, ongoing research aims to find a more universally applicable cure.

The case of the Oslo patient serves as a valuable contribution to our understanding of HIV remission, shedding light on the complex interactions of genetics, immune responses, and therapeutic interventions. Despite the hurdles that remain, the pursuit of a true cure for HIV continues, as researchers work to improve the lives of those affected by the virus.